Autologous transfusion recovery of WBC-reduced high-concentration platelet concentrates.
This study evaluates the recovery and survival of high-concentration platelets (HCPs) compared to standard apheresis platelets (APCs) in a double-label autologous human system. Nine HCP units paired with APC units were stored, labeled with either 51Cr and 111In, and returned, and recovery and survival were determined. Standard in vitro platelet biochemical and functional parameters were monitored over the storage period and evaluated in a secondary analysis. Three each HCP units containing more than 2.2 x 10(11), 1.5 x 10(11) to 2.1 x 10(11), and 0.8 x 10(11) to 1.1 x 10(11) platelets in 59.4 +/- 2.5 mL were stored for 1, 2, or 5 days, respectively, and simultaneously with matched APC units (3.8 x 10(11) platelets, 282 mL). Recoveries were 72.3 +/- 8.6, 60.8 +/- 14.6, and 52.5 +/- 6.7 percent for HCPs, respectively; and 59.4 +/- 6.4 percent for APCs (p=0.37). HCP survivals were 202.0 +/- 14.9, 204.9 +/- 10.2, and 162.6 +/- 17.0 hours; APC survivals were 155.4 +/- 20.3 hours (p=0.001). Secondary analysis with P-selectin added as a predictor in the model resulted in significant difference in recoveries for Day 1 HCPs versus Day 5 APCs (p=0.024) with no difference shown for HCPs on Days 2 or 5 versus APCs. No significant difference was found in survival (p=0.16). HCPs may be stored 24 hours for high yield, 48 hours for intermediate yield, and up to 5 days for yields less than 1.6 x 10(11) platelets per bag with equivalent to superior recovery and survival of platelets in the autologous transfusion model compared to APCs.